President Wen visited a manufacturer of corona vaccine, “Samsung was very helpful”

On the afternoon of the 18th, President Moon Jae-in visits Poonglim Pharmatech, a production facility for the least residual type (LDS) syringe for corona 19 vaccination, in Gunsan, Jeollabuk-do, and demonstrates a comparison between a regular syringe and a minimum residual type syringe. 2021.2.18/News1 © News1-President Moon Jae-in said on the 18th, “I will surely lead to success with vaccination starting on the 26th,” regarding the novel coronavirus infection (Corona 19).

President Moon visited Poonglim Pharmatech, a manufacturer of LDS (Low Dead Space) vaccine syringes in Gunsan, Jeollabuk-do, and said, “The government has secured a sufficient amount of vaccines and syringes, and prepared a vaccination plan.” The minimum residual type syringe is a syringe that minimizes the amount of vaccine remaining in the syringe. 5 people can be inoculated with one bottle of vaccine with a regular syringe, but 6 people can be inoculated with a minimal residual syringe.

Poonglim Pharmatech has been equipped with a production system capable of producing at least 10 million syringes per month by shortening the development period from at least one year to one month with support from the Ministry of Small and Medium Venture Businesses and Samsung Electronics last year. The export contract is expected to continue with approval from the US Food and Drug Administration (FDA). In the course of negotiations with Pfizer, the government implemented the early introduction of the vaccine under the condition of supplying the least residual syringe to Pfizer. President Moon said, “We are very happy to inform the public about the importance of syringes, which are essential for vaccination, and the excellence of our products.” “Behind the innovation achievements of Poonglim Pharmatech, there was a win-win cooperation between large companies, SMEs, and the government.” “Samsung first predicted that the demand for minimal residual syringes will increase, and by acknowledging Poonglim Pharmatech’s technological prowess, we led the mass production of excellent products through all-round cooperation, such as supporting automation of production lines and mold technology.” ) The help of the Ministry of Food and Drug Safety and Samsung Bioepis was great.” Hee-min Cho, CEO of Poonglim Pharmatech, Jong-ho Kim, head of Samsung Electronics Smart Factory Support Center, and Han-seung Ko, President of Samsung Bioepis, attended the event.